ICER to Review Treatments for Psoriasis

-Dates for previously announced review of treatments for non-small cell lung cancer also posted-

Boston, Mass., June 3, 2016 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of several existing and emerging therapies for the treatment of plaque psoriasis and psoriatic arthritis. The report will include a systematic review of the comparative clinical effectiveness and cost-effectiveness of selected treatments. A preliminary list of treatments to be reviewed will be posted as part of a draft scoping document scheduled to be released on June 24, 2016.

This report will be the subject of a November 2016 meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in Boston, MA. During the meeting, the independent Council will deliberate and vote on the comparative clinical effectiveness and value of the treatments included in the review. The Council will discuss the implications of the votes for policy and practice with a roundtable of clinical experts and patients to provide guidance to patients, clinicians, insurers, and policymakers confronted with decisions on how best to manage psoriasis to ensure optimal patient outcomes.

ICER is currently engaging a variety of stakeholders, including patients, physicians, and manufacturers, to provide input to the development of the scope. A preliminary scoping document will be posted to the ICER website for public comment on June 24, 2016. After the scoping document is posted, all stakeholders will have one week to submit suggestions and refinements to ensure that the report provides a comprehensive analysis of the considerations and issues of greatest importance.

Key dates for the psoriasis report:

Draft Scoping Document Posted: June 24, 2016
Public Comment on Scope: June 24, 2016- July 1, 2016
Final Scoping Document Posted: July 8, 2016
Draft Evidence Report and Draft Voting Questions Posted: September 29, 2016
Public Comment on Draft Evidence Report and Voting Questions: September 29, 2016- October 13, 2016
Evidence Report Posted: October 28, 2016
Public Meeting of the New England CEPAC: November 18, 2016

More information on the review of treatments for psoriasis will be posted to the ICER website as it becomes available.

As previously announced, ICER is conducting a review of existing and emerging therapies for the treatment of non-small cell lung cancer. The report will be the subject of a meeting of the Midwest CEPAC. Key dates for the review are listed below:

Draft Scoping Document Posted: June 13, 2016
Public Comment on Scope: June 13, 2016- June 20, 2016
Final Scoping Document Posted: June 27, 2016
Draft Evidence Report and Draft Voting Questions Posted: August 19, 2016
Public Comment on Draft Evidence Report and Voting Questions: August 19, 2016-September 2, 2016
Evidence Report Posted: September 28, 2016
Public Meeting of the Midwest CEPAC: October 20, 2016

More information on the review of treatments for non-small cell lung cancer will be posted to the ICER website as it becomes available.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.